Objective: Post-Transplant Diabetes Mellitus (PTDM) occurs in an estimated 20-40% of lung transplantation within five years, and hyperglycemia adversely affects outcomes, including rejection, infection, cardiovascular events, and mortality. Whereas continuous glucose monitoring (CGM) is common in patients with type 1 and type 2 diabetes mellitus, there is a significant knowledge gap in its application to PTDM. The objective of this study was to evaluate the performance of CGM in detecting hypoglycemia and hyperglycemia in the early post-lung transplantation period, compared with self-monitoring blood glucose.

Research and Design Methods: We conducted a prospective pilot study with patients aged 18-75 who underwent lung transplantation and had hyperglycemia managed with insulin. Enrolled patients wore a blinded CGM at discharge and self-monitored glucose levels at home for 10 days. Data were summarized according to the following categories and compared across both tests using the paired t-test: % time in range (70-180 mg/dl); % high (181-250 mg/dl); % very high (>250 mg/dl); % low (50-69 mg/dl); % very low (<50 mg/dl).

Results: The sample included 15 patients (mean age 58.6 years; 53.3% men; 73.3% with pre-transplantation diabetes). There was a significantly higher rate of detection for hyperglycemia with CGM use vs. self-monitored blood glucose. For the “% very high” group, the mean difference was 7.12, (95% confidence interval [CI], 1.8-12.4), and for the “% high” group, the mean difference was 11.1, (95% CI, 3.5-18.8), and for the combined group, “% high and % very high”, the mean difference was 18.3, (95% CI: 7.37-29.24). There was no statistically significant difference for the “% low and % very low” groups.

Conclusions: CGM demonstrated a higher rate of detection for hyperglycemia compared to self-monitoring blood glucose. The mean difference for hypoglycemia detection was not significant. Larger studies are required to provide statistically meaningful conclusions about CGM in PTDM.

Disclosure

J.M.Munoz pena: None. H.Rasmussen: None. R.G.Salloum: None. M.Leong: None. K.A.Algarra: None.

Funding

Dexcom, Inc. (MM130159)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.